Perturbed NK-cell homeostasis associated with disease severity in chronic neutropenia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
03 02 2022
Historique:
received: 07 07 2021
accepted: 24 09 2021
pubmed: 27 10 2021
medline: 8 3 2022
entrez: 26 10 2021
Statut: ppublish

Résumé

Neutrophils have been thought to play a critical role in terminal differentiation of NK cells. Whether this effect is direct or a consequence of global immune changes with effects on NK-cell homeostasis remains unknown. In this study, we used high-resolution flow and mass cytometry to examine NK-cell repertoires in 64 patients with neutropenia and 27 healthy age- and sex-matched donors. A subgroup of patients with chronic neutropenia showed severely disrupted NK-cell homeostasis manifesting as increased frequencies of CD56bright NK cells and a lack of mature CD56dim NK cells. These immature NK-cell repertoires were characterized by expression of the proliferation/exhaustion markers Ki-67, Tim-3, and TIGIT and displayed blunted tumor target cell responses. Systems-level immune mapping revealed that the changes in immunophenotypes were confined to NK cells, leaving T-cell differentiation intact. RNA sequencing of NK cells from these patients showed upregulation of a network of genes, including TNFSF9, CENPF, MKI67, and TOP2A, associated with apoptosis and the cell cycle, but different from the conventional CD56bright signatures. Profiling of 249 plasma proteins showed a coordinated enrichment of pathways related to apoptosis and cell turnover, which correlated with immature NK-cell repertoires. Notably, most of these patients exhibited severe-grade neutropenia, suggesting that the profoundly altered NK-cell homeostasis was connected to the severity of their underlying etiology. Hence, although our data suggest that neutrophils are dispensable for NK-cell development and differentiation, some patients displayed a specific gap in the NK repertoire, associated with poor cytotoxic function and more severe disease manifestations.

Identifiants

pubmed: 34699594
pii: S0006-4971(21)01789-4
doi: 10.1182/blood.2021013233
doi:

Substances chimiques

HAVCR2 protein, human 0
Hepatitis A Virus Cellular Receptor 2 0
Ki-67 Antigen 0
Receptors, Immunologic 0
TIGIT protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

704-716

Informations de copyright

© 2022 by The American Society of Hematology.

Auteurs

Ebba Sohlberg (E)

Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Aline Pfefferle (A)

Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Eivind Heggernes Ask (E)

Department of Cancer Immunology, Institute for Cancer Research.
Institute of Clinical Medicine, and.

Astrid Tschan-Plessl (A)

Department of Cancer Immunology, Institute for Cancer Research.

Benedikt Jacobs (B)

Department of Cancer Immunology, Institute for Cancer Research.

Herman Netskar (H)

Department of Cancer Immunology, Institute for Cancer Research.
Institute of Clinical Medicine, and.

Susanne Lorenz (S)

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Minoru Kanaya (M)

Department of Cancer Immunology, Institute for Cancer Research.

Mizuha Kosugi-Kanaya (M)

Department of Cancer Immunology, Institute for Cancer Research.

Stephan Meinke (S)

Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, and.

Anette Mörtberg (A)

Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden.
Medical Unit Clinical Immunology and Transfusion Medicine and.

Petter Höglund (P)

Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, and.
Medical Unit Clinical Immunology and Transfusion Medicine and.

Mikael Sundin (M)

Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden.
Section of Pediatric Hematology/Immunology/Hematopoietic Cell Transplantation, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

Göran Carlsson (G)

Section of Pediatric Hematology/Immunology/Hematopoietic Cell Transplantation, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

Jan Palmblad (J)

Department of Medicine, Karolinska Institutet, Stockholm, Sweden; and.
The Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Karl-Johan Malmberg (KJ)

Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Department of Cancer Immunology, Institute for Cancer Research.
Institute of Clinical Medicine, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH